Klivira
Request demo

Optimizing Ultomiris Prior Authorization for Gastroenterology

Navigating **Ultomiris prior authorization for gastroenterology** presents unique challenges, demanding precise documentation and workflow efficiency to ensure patient access to critical therapies.

For revenue cycle directors and prior authorization coordinators in gastroenterology, managing high-volume drug authorizations like Ultomiris requires robust systems. The complexities of specialty GI drugs, coupled with evolving payer policies, can lead to significant administrative burden and treatment delays, impacting both patient care and financial health.

The Prior Authorization Imperative for Ultomiris

Ultomiris stands as a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Its widespread use necessitates rigorous documentation and efficient processing to avoid treatment delays, ensure continuity of care, and maintain revenue integrity for practices managing complex conditions.

Gastroenterology's Unique Prior Authorization Landscape

Gastroenterology practices face substantial prior authorization burdens across a spectrum of services, including biologics for inflammatory bowel disease (IBD), advanced imaging (e.g., MR enterography), and specialized endoscopic procedures. The chronic nature of many GI conditions often entails periodic re-authorizations, adding to the administrative load. Payer policies frequently mandate adherence to clinical guidelines from bodies like ACG and AGA.

Key Documentation Requirements for GI Specialty Drugs

  • Diagnosis confirmation via endoscopic, imaging, or histologic evidence.
  • Disease severity assessment using validated scores (e.g., Mayo score for UC, CDAI for Crohn's).
  • Documentation of prior conventional-therapy trials and adherence to step therapy protocols.
  • Pre-initiation screening results, such as for tuberculosis and hepatitis.
  • Genotype and fibrosis stage documentation for Hepatitis C direct-acting antivirals.
  • Medical necessity criteria for advanced imaging or specific endoscopic procedures.

Common Prior Authorization Denial Reasons in Gastroenterology

  • Non-compliance with payer-mandated step therapy for IBD biologics, including biosimilar substitution requirements.
  • Insufficient documentation of disease severity, prior therapy failure, or pre-treatment screening.
  • Inappropriate-use criteria for advanced imaging or capsule endoscopy, lacking clinical correlation.
  • Misclassification of treatment-naive versus treatment-experienced status, particularly for IBD biologics and Hep C DAAs.
  • Gaps in medical necessity justification for specialty drugs treating functional GI disorders.

Klivira's Solution for Gastroenterology Prior Authorization

Klivira's platform is purpose-built to streamline prior authorization workflows specific to gastroenterology. We integrate ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing, automate treatment-status classification from EMR medication histories, and manage periodic re-authorization cycles for chronic therapies. Our system also addresses the medical-vs-pharmacy benefit split for biologics, ensuring correct submission pathways.

Seamless EMR Integration for Enhanced Efficiency

Klivira leverages SMART on FHIR-enabled integrations to connect directly with leading EMR systems used by gastroenterology practices. This robust connectivity automates the extraction of clinical data, reducing manual entry errors and ensuring that all required documentation, from diagnostic reports to treatment histories, is accurately compiled and submitted for high-volume drug prior authorizations, including Ultomiris.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics?

Klivira's system accounts for the medical-vs-pharmacy benefit split common in gastroenterology, routing requests appropriately whether a biologic is provider-administered (medical benefit) or self-administered (pharmacy benefit). This ensures correct submission pathways regardless of the administration mode, minimizing delays.

Can Klivira help with re-authorization for chronic GI conditions?

Yes, Klivira specifically supports periodic re-authorization workflows for chronic GI treatments, such as IBD biologics. Our platform tracks authorization expiry dates and proactively initiates re-submission processes, guiding practices to collect and submit required updated documentation efficiently.

What EMRs does Klivira integrate with for gastroenterology practices?

Klivira offers robust integrations with major EMR systems using SMART on FHIR standards, enabling seamless data exchange. This automation extracts clinical information necessary for prior authorization requests in gastroenterology, reducing manual effort and improving data accuracy. For specific EMRs, please visit our integrations page.

How does Klivira address step therapy requirements for GI biologics?

Klivira incorporates ACG/AGA-guideline-aware step therapy logic, helping gastroenterology practices navigate complex payer policies for IBD biologics. The platform guides users through required conventional therapy trials and biosimilar considerations, ensuring compliance and reducing the risk of denials.

Does Klivira support prior authorization for advanced GI imaging and procedures?

Yes, Klivira's platform is designed to manage prior authorizations for a wide range of GI services, including advanced imaging like MR enterography and specific endoscopic procedures. Our system helps ensure that medical necessity criteria and required supporting documentation are met for these high-volume PA categories.

Related coverage

Other ultomiris prior authorization by payer

Other ultomiris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo